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Abstract
Human immunodeficiency virus (HIV) infection substantially elevates diffuse large B-cell 
lymphoma (DLBCL) risk, but its impact on the distinct DLBCL subtypes defined by cell of origin 
is unclear. We compared DLBCL molecular characteristics and prognosis in 51 HIV-infected and 
116 HIV-uninfected cases diagnosed during 1977-2003. Using immunohistochemistry to classify 
cell of origin based on the Tally algorithm, activated B-cell (ABC)-DLBCL was substantially 
more common in HIV-infected (83%) than in HIV-uninfected (54%) cases (p< 0.001). Epstein-
Barr virus (EBV) was detected in 63% of DLBCLs in HIV-infected cases, occurring almost 
exclusively in ABC-DLBCL (74% vs. 13% of germinal center B-cell [GCB]-DLBCL, p=0.002), 
but was rarely detected in DLBCLs among HIV-uninfected cases (3%). Among HIV-uninfected 
cases, MYC/IgH[t(8;14)(q24;q32)] and IgH/BCL2[t(14;18)(q32;q21)] translocations were 
significantly more common and BCL6/IgH[t(3;14)(q27;q32)] significantly less common in GCB-
DLBCL than in ABC-DLBCL (p= 0.010, < 0.001 and = 0.039, respectively). Among HIV-
infected cases, translocations other than MYC/IgH[t(8;14)(q24;q32)] (21%) were rare (≤6%) and 
unrelated to cell of origin. ABC-DLBCL was associated with adverse overall survival compared 
with GCB-DLBCL regardless of HIV status (pHIV-infected= 0.066;pHIV-uninfected= 0.038). Our data 
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demonstrate key differences in the molecular characteristics, cell of origin and prognosis of 
DLBCL by HIV status in the pre-highly active antiretroviral therapy (HAART) and pre-rituximab 
era, supporting biologic differences in lymphomagenesis in the presence of HIV.
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Introduction
Diffuse large B-cell lymphoma (DLBCL), the most common histologic type of non-Hodgkin 
lymphoma (NHL) in both immunocompetent and immunosuppressed individuals, is a 
clinically and molecularly heterogeneous entity. In the general population, 5-year relative 
survival is 59% [1], though the clinical course is highly variable. Gene expression profiling 
of DLBCLs has revealed distinct disease subtypes that derive from B-cells at varying stages 
of differentiation, specifically germinal center B-cell (GCB)-DLBCL, post-germinal center 
or activated B-cell (ABC)-DLBCL, and the rare primary mediastinal large B-cell lymphoma 
[2,3]. People with ABC-DLBCL have a substantially worse prognosis than people with 
GCB-DLBCL or primary mediastinal large B-cell lymphoma, and certain molecular 
characteristics appear distinctly related to the cell of origin, such as the association of 
BCL2and MYCtranslocations with GCB-DLBCL and constitutive activation of the nuclear 
factor- κB (NF-κB) pathway in ABC-DLBCL [4–7].
Human immunodeficiency virus (HIV) causes extensive immune dysfunction, including loss 
of T-cell function, altered cell signaling and chronic B-cell activation, with accompanying 
increases in B-cell proliferation, differentiation and apoptosis [8,9]. People with advanced 
HIV infection have 30-100-fold increased risk for DLBCL [10] and tend to present with 
aggressive disease that is more frequently of extranodal origin than in the general population 
[8]. Epstein- Barr virus (EBV), uncommon in DLBCLs in HIV-uninfected individuals, is 
detectable in over 80% of DLBCLs in HIV-infected individuals [11].
Previous studies of the cell of origin of DLBCLs in HIV-infected individuals have yielded 
varying results. Several studies have suggested the predominance of post-germinal center 
DLBCL based on gene expression profiling [12], immunohistochemistry [13] or 
demonstration of immunoglobulin gene somatic hypermutation [14], but other studies have 
not supported those findings [15–22]. Several gene expression [12,23] and 
immunohistochemistry-based [13,17,18,24] studies have reported an intermediate phenotype 
with increased co-expression of GCB and ABC markers, which complicates classification 
by cell of origin. Finally, studies of the prognostic significance of molecular characteristics 
have been conflicting [17–19], and few studies have related cell of origin to other 
clinicopathologic characteristics [13,17,20].
To advance understanding of the pathogenetic contribution of HIV to lymphomagenesis, we 
classified DLBCLs by cell of origin in archived specimens from HIV-infected and HIV-
uninfected cases using the most current immunohistochemistry-based methods [25], 
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evaluated the prognostic significance of this cell of origin classification, and compared the 
frequency of key molecular and viral characteristics.
Methods
Study population
Cases were identified through the Los Angeles Residual Tissue Repository (LA RTR), 
directed and maintained at the University of Southern California Keck School of Medicine. 
The LA RTR collects formalin-fixed, paraffin-embedded tissue specimens for Los Angeles 
County patients that otherwise would have been discarded by local area pathology 
departments (e.g. for logistical or storage constraints), and links the specimens to the 
University of Southern California Cancer Surveillance Program (USC-CSP, the population-
based cancer registry for Los Angeles, one of the National Cancer Institute Surveillance, 
Epidemiology and End-Results [SEER] cancer registries), to obtain patient information [26]. 
The linkage is possible because the USC-CSP collects pathology reports on patients 
diagnosed in Los Angeles County since 1972 as part of the cancer reporting process.
For all patients with a primary diagnosis of NHL who had an available specimen with 
sufficient tumor tissue in the LA RTR as of 2010 (n= 351), multi-tumor blocks were created 
by assembling a tumor tissue specimen (up to 8 mm × 3 mm) from each patient in array 
fashion, with 8–10 samples per block. Samples were organized by NHL subtype, based on 
initial review of pathology reports and hematoxylin and eosin stained slides by an expert 
hematopathologist (L. Weiss), and by HIV status, as confirmed by pathology report and 
USC-CSP abstract review (D. Hawes).
Eligible patients for this study included all patients diagnosed with primary DLBCL based 
on pathology report and diagnostic slide review (n= 180). DLBCL diagnoses were 
confirmed with additional immunophenotyping (see laboratory methods below), resulting in 
the exclusion of three patients, who were determined to have another NHL subtype, yielding 
a population of 177 patients for molecular studies (described below). Linkage with the 
SEER registry database provided information on sex; race/ethnicity; socioeconomic status; 
age, date and primary site of DLBCL diagnosis; occurrence of other primary malignancies 
before or after DLBCL diagnosis; first course of DLBCL treatment (chemotherapy, 
immunotherapy, radiotherapy); and follow-up for vital status. Socioeconomic status was 
derived from census tract-level information on educational attainment and household 
income. All census tracts were ranked twice, first by the weighted average highest level of 
education attained by adult residents, and second by median household income. These two 
ranks were summed, and the socioeconomic status was assigned by dividing the summed 
ranking into quintiles. The study was conducted according to a protocol reviewed and 
approved by the University of Southern California Institutional Review Board and National 
Cancer Institute Office of Human Subjects Research.
Laboratory analysis
Immunohistochemical staining was conducted for CD20 and nine key markers of B-cell 
differentiation, including four germinal center B-cell markers (BCL6, CD10, GCET1, 
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LMO2) and five activated B-cell markers (BCL2, FOXP1, CD138, MUM1, TP53), 
according to standard methods. Briefly, 5 μm sections were cut from the multi-tumor blocks, 
deparaffinized and pretreated for antigen retrieval. Immunohistochemical staining was 
conducted using a Dako autostainer, with incubation of primary antibodies for 20–30 min at 
room temperature, followed by a secondary antibody. Details of the antibodies and antigen 
retrieval are provided in Table II. All reactivities were visualized using chromogen 
diaminobenzidine tetrahydrochloride (DAB), with hematoxylin as a counterstain.
Slides were evaluated by an expert hematopathologist (L. Weiss). Ten people were excluded 
due to insufficient or poor quality tissue, resulting in a final analytic population of 167 
individuals (51 HIV-infected, 116 HIV-uninfected). Within this analytic population, 
successful staining was achieved for ≥ 95% of samples for all markers. Based on consensus 
in the literature at the time of slide review, samples with ≥ 30% tumor cells stained were 
considered positive for BCL6, CD10, LMO2 and CD138; ≥ 60% for GCET1 and BCL2; or 
≥ 75% for FOXP1, MUM1 and TP53 [25]. Slides from 16 randomly selected individuals 
were re-evaluated separately without knowledge of the original interpretation. Agreement 
between the independent evaluations was ≥ 94% for all markers except LMO2 (88%) and 
CD138 (81%).
The presence of EBV was evaluated using EBV-encoded RNA-1 (EBER) in 
situhybridization according to standard methods [27], with successful completion for all 167 
samples. Cases were considered EBV+ if all or nearly all tumor cells were stained. 
Fluorescence in situhybridization (FISH) was used to detect common NHL-associated 
translocations including MYC/IgH[t(8;14)(q24;q32)], IgH/BCL2[t(14;18)(q32;q21)] and 
BCL6/IgH[t(3;14)(q27;q32)], according to standard methods [28]. Probes included the LSI 
BCL6 (ABR) dual color breakapart probe; the LSI IGH/BCL2 dual color, dual fusion 
translocation probe; and the LSI MYC dual color, breakapart rearrangement probe, all 
obtained from Abbott Molecular (Des Plaines, IL). FISH was conducted successfully for 
89% of patients for MYC/IgH[t(8;14)(q24;q32)], 93% for IgH/BCL2[t(14;18)(q32;q21)] and 
86% for BCL6/IgH[t(3;14)(q27;q32)].
Statistical analysis
DLBCLs were distinguished by cell of origin into GCB- and ABC-DLBCL according to the 
Tally algorithm [25]. Briefly, cases were classified by counting the number of positive GCB 
(GCET1 and CD10) and ABC (FOXP1 and MUM1) antibodies and assigning the category 
with the higher score [25]. In the case of an equal number of GCB and ABC antibodies, 
expression of another GCB marker (LMO2) determined the cell of origin (15 HIV-infected, 
26 HIV-uninfected).
Fisher's exact test was used to compare: (1) expression frequency of individual markers by 
HIV status, (2) cell of origin category by HIV status and (3) correlates of cell of origin (i.e. 
presence of translocations, EBV status and primary site) for HIV-infected and HIV-
uninfected people separately. Overall survival (OS), defined as the time from DLBCL 
diagnosis to death or last follow-up, by cell of origin and HIV status was estimated using the 
Kaplan-Meier method.
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Differences among groups were assessed using the (univariate) log-rank test and 
multivariate Cox proportional hazards regression, adjusting for race/ethnicity (White, non-
Hispanic; Hispanic; other/unknown), socioeconomic status, age at DLBCL diagnosis (< 40, 
≥ 40 years), year of DLBCL diagnosis (≤ 1990, 1991–1995, ≥ 1996) and receipt of initial 
therapy. We conducted two sensitivity analyses. First, because of demographic differences 
among HIV-infected and HIV-uninfected individuals, all comparisons by HIV status were 
repeated restricting HIV-uninfected individuals to males aged < 60 years. Second, we 
restricted analyses of OS to the 72% of cases (40 HIV-infected, 80 HIV-uninfected) who 
were reported to have received initial immunotherapy and/or chemotherapy. Results from 
both of these sensitivity analyses were consistent with those obtained in our main analyses 
with the full study population and thus are not presented. Two-sided p-values < 0.05 were 
considered statistically significant. Analyses were conducted using SAS software version 
9.2 (SAS Institute, Cary, NC).
Role of the funding source
The funding source had no role in the study design; collection, analysis and interpretation of 
data; writing of the report; or decision to submit the paper for publication.
Results
All HIV-infected cases were male, with a median age at DLBCL diagnosis of 37 years 
(range 25–58 years) and median year of diagnosis of 1992 (range 1987–1998; largely prior 
to the introduction of highly active antiretroviral therapy [HAART] to treat HIV and 
rituximab to treat DLBCL) (Table I). In contrast, HIV-uninfected cases were evenly divided 
by sex, tended to be older (median age: 65 years, range 16–90) and were diagnosed over a 
wider range of time (median year: 1992, range 1977–2003; also largely in the pre-rituximab 
era). HIV-infected individuals were predominantly diagnosed with DLBCL of primary 
extranodal origin (61%), with 20% occurring in the brain or central nervous system, 14% in 
the lower gastrointestinal tract and 8% in the stomach, whereas only 39% of HIV-uninfected 
individuals were diagnosed with DLBCL of primary extranodal origin, with no particularly 
common sites. All HIV-infected and 99 (85%) HIV-uninfected cases were deceased as of 
2011.
We compared the expression frequency of individual markers of B-cell differentiation by 
HIV status (Table II). Compared with HIV-uninfected cases, DLBCLs in HIV-infected cases 
generally were less likely to express germinal center markers, particularly BCL6 (28% vs. 
46%, p= 0.039) and GCET1 (12% vs. 27%, p= 0.042) and more likely to express activated 
B-cell markers, particularly MUM1 (69% vs. 48%, p= 0.018).
Using the Tally algorithm to classify DLBCLs according to cell of origin [25], HIV-infected 
cases were more likely to have ABC-DLBCL than HIV-uninfected cases (HIV-infected: 
83%, HIV-uninfected: 54%, p< 0.001). Among HIV-infected individuals, only 31% of the 
DLBCLs had one of the three translocations we evaluated, most commonly MYC/IgH, and 
the presence of translocations was not related to cell of origin (p= 0.648; Table III). In 
contrast, 47% of the DLBCLs among HIV-uninfected individuals had at least one of the 
three translocations we evaluated, and the presence of translocations was strongly related to 
Morton et al. Page 5













cell of origin (p= 0.009). Specifically, among HIV-uninfected cases, the MYC/IgH[t(8;14)
(q24;q32)] and IgH/BCL2[t(14;18)(q32;q21)] translocations were significantly more 
common in GCB- than ABC-DLBCL (p= 0.010 and < 0.001, respectively), and the BCL6/
IgH[t(3;14)(q27;q32)] translocation was significantly more common in ABC-DLBCL (p= 
0.039). EBV was detected in 63% of DLBCLs in HIV-infected cases and occurred almost 
exclusively in the ABC type (p= 0.002), whereas EBV was rarely detected in DLBCLs of 
HIV-uninfected cases (3%). In all cases, regardless of HIV status, ABC-DLBCL was 
somewhat more likely to be of primary extranodal origin than GCB-DLBCL, but these 
differences were not statistically significant. Patient characteristics such as sex and age were 
not significantly related to cell of origin among HIV-infected and HIV-uninfected cases.
HIV-infected cases had worse OS compared with HIV-uninfected cases (hazard ratio [HR] = 
3.82, 95% confidence interval [CI] 2.57-5.67). Among both HIV-infected and HIV-
uninfected cases, ABC-DLBCL was associated with adverse OS compared with GCB-
DLBCL (HIV-uninfected: HR = 1.64, 95% CI 1.03-2.62, p= 0.038; HIV-infected: HR = 
2.38, 95% CI 0.95–5.99,p= 0.066) (Figure 1). Patterns were similar in analyses stratified by 
calendar year of DLBCL diagnosis (≤ 1990, 1991-1995, ≥ 1996), and for analyses of HIV-
uninfected individuals restricted to males aged < 60 years.
To address the potential for increased frequency of an intermediate phenotype (co-
expression of GCB and ABC markers) in DLBCLs in HIV-infected individuals, we 
compared our classification of cell of origin to the immunostain algorithms reported in 
previous studies. Most patients with the phenotype BCL6–/MUM1+/CD138 – described by 
Carbone et al.[13] were classified as ABC-DLBCL using the Tally algorithm (among HIV-
infected: 22 [43%] cases were BCL6-/MUM1+/CD138–, of which 21 were classified as 
ABC-DLBCL; among HIV-uninfected: 32 [28%] were BCL6-/MUM1+/CD138–, of which 
20 were classified as ABC-DLBCL). The pattern was similar for the phenotype described by 
Hoffmann et al.[18](CD10 + and/or BCL6 + and MUM1 + and/or CD138+; nine [18%] 
HIV-infected, all classified as ABC-DLBCL; 24 [21%] HIV-uninfected, of which 18 were 
classified as ABC-DLBCL). In contrast, few cases were identified as CD10+/BCL6+/
MUM1 + based on Chadburn et al.[17](one [2%] HIV-infected, five [4%] HIV-uninfected) 
in our study, and we could not directly compare our results to Madan et al.[24] because we 
did not include all necessary immunostains.
Discussion
In a direct comparison of DLBCLs in HIV-infected and HIV-uninfected individuals, we 
observed striking differences in the distributions of certain molecular characteristics, 
supporting alternative pathways of lymphomagenesis in disease subgroups defined by both 
cell of origin and HIV status. Specifically, DLBCLs in HIV-infected cases were 
predominantly of ABC origin, with EBV-positivity almost completely concordant with the 
ABC phenotype. DLBCLs in HIV-infected cases tended to lack IgH/BCL2and BCL6/
IgHtranslocations, regardless of the cell of origin. In contrast, DLBCLs in HIV-uninfected 
cases were approximately evenly divided by cell of origin, with the BCL6/IgHtranslocation 
more common in ABC-DLBCL and the IgH/BCL2translocation slightly more common in 
GCB-DLBCL. The MYC/IgHwas more common in GCB-DLBCL, regardless of HIV status. 
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These results provide further insight into the pathogenetic mechanisms of lymphomagenesis 
in HIV-infected DLBCLs occurring during the pre-HAART and pre-rituximab era. The first 
distinct pattern of lymphomagenesis in HIV-infected cases, constituting the majority of 
DLBCLs, is driven by EBV, lacks typical lymphomagenic lesions and is of the ABC-type, 
with the central nervous system being the most frequent extranodal site. In contrast, the 
second pattern, similar to HIV-uninfected cases, is independent of EBV, includes typical 
genetic alterations, and is evenly distributed between ABC- and GCB-types.
The predominance of the ABC phenotype that we observed in HIV-infected cases is 
consistent with some [12–14], but not all [15-22], previous studies of DLBCL by HIV 
status, though direct comparison of our results with some studies is hindered by inclusion of 
histologies other than DLBCL, evaluation of relatively few cases or, for 
immunohistochemistry-based studies, use of various antibodies (alone or in combination, 
with a range of cut-offs to determine positivity) to identify the cell of origin. Although we 
identified some DLBCLs with the “intermediate” phenotypes described previously, most of 
these patients were classified as ABC-DLBCL by the Tally algorithm in our study. Thus, 
our data do not clearly support previous studies that have suggested a particular propensity 
of DLBCLs in HIV-infected individuals to express an intermediate phenotype with 
increased co-expression of GCB and ABC markers [12,13,17,18,23,24]. However, DLBCLs 
that cannot be classified by cell of origin also have been reported in the general population 
[7], suggesting that further gene expression profiling studies with the ability to evaluate an 
intermediate phenotype with sufficient numbers of HIV-infected and HIV-uninfected cases 
are warranted.
Constitutive activation of the NF-κB pathway is one of the most important features of ABC-
DLBCL, based on increased expression of a range of NF-κB target genes in microarray 
analyses and dependence of ABC-DLBCL cell lines on NF-κB activity [7]. EBV is known 
to be a key driver of lymphomagenesis in immunosuppressed individuals [11], and we 
demonstrated a nearly exclusive association between EBV and ABC-DLBCL in the HIV-
infected cases in our study. Our results are consistent with several previous studies that also 
reported higher EBV prevalence in ABC- than GCB-DLBCL [13,17,20,22], and may 
support the importance of the transforming EBV protein LMP1 in activating the NF-κB 
pathway [11], preferentially leading to ABC-DLBCL, although data on NF-κB were not 
available. EBV also may preferentially lead to ABC-DLBCL by down-regulating BCL6 and 
up-regulating BCL2 [29-32]. In HIV-uninfected individuals, we observed a higher 
frequency of the BCL6/IgHin ABC-DLBCL than in GCB-DLBCL, which also is consistent 
with previous research [33]. Interestingly, although the BCL6/IgHoccurred in DLBCLs of 
only two HIV-infected cases, both were EBV- and had the ABC phenotype.
GCB-DLBCL is also associated with a range of genetic alterations, including translocations 
involving the BCL2and MYConcogenes [6,7]. In our study, the MYC/IgHwas indeed more 
common in GCB-DLBCL, regardless of HIV status. In contrast, we observed a higher 
frequency of the IgH/BCL2translocation in GCB-DLBCL only in HIV-uninfected cases.
The ABC phenotype was associated with adverse prognosis compared with GCB-DLBCL in 
our study, regardless of HIV status, although the associations were of borderline statistical 
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significance. Although the prognostic significance of the cell of origin classification 
independent of the International Prognostic Index is well-established in HIV-uninfected 
cases [25], some studies [18,19,22], but not all [17], have reported a similar association in 
HIV-infected cases. These inconsistent results may be related to the use of different 
classification approaches to identify the cell of origin. Additionally, the role of underlying 
differences in patients' immune status may explain some inconsistencies, because the risk of 
DLBCL in HIV-infected individuals is related to immune suppression [34], and DLBCL 
risks have declined since the introduction of HAART [10]. Almost all cases in our study 
were diagnosed before 1996, so further studies in the HAART era that can directly evaluate 
the relationship of molecular characteristics to the degree of immunosuppression are 
warranted, and would be hypothesized to observe a higher proportion of GCB-DLBCL in 
HIV-related cases due to improved immune function.
The cell of origin may have been misclassified for some cases in our study because we used 
immunohistochemistry rather than gene expression profiling [35]. However, the Tally 
algorithm has the best concordance with gene expression profiling studies to date [25], and 
does not rely on BCL6, the germinal center marker associated with the most rapid antigen 
degradation [36]. In addition, we included blinded duplicates to ensure the reproducibility of 
our immunostain interpretation. Some misclassification also could have occurred because 
we used different cut-offs to determine positivity for FOXP1 (80%), MUM1 (80%) and 
GCET1 (60%) since the Tally algorithm (30% cut-off for all immunostains) was published 
after we completed immunostain interpretation. The difference in the cut-offs would bias 
away from classification of ABC-DLBCL because we used more stringent criteria for the 
two ABC markers, and thus our identification of a high proportion of ABC-DLBCL in HIV-
infected cases is likely conservative. Our analyses of OS should be interpreted cautiously 
because we lacked detailed clinical information (e.g. International Prognostic Index 
parameters, DLBCL treatment, CD4 count, HIV treatment) and because nearly all HIV-
infected cases were diagnosed before the introduction of HAART, and nearly all patients 
were diagnosed prior to the introduction of rituximab as standard therapy for DLBCL. 
Finally, because cases identified for this study had tissue specimens that otherwise would 
have been discarded by local area pathology departments (e.g. for logistical or storage 
constraints), our population was not necessarily representative of all DLBCL cases 
diagnosed in the LA SEER registry.
In summary, our results provide strong evidence for both similarities and differences in the 
molecular characteristics of DLBCLs in HIV-infected and HIV-uninfected individuals. 
Specifically, among HIV-infected cases, DLBCLs were predominantly EBV+, with nearly 
all EBV+ DLBCLs of the ABC-type and lacking typical lymphomagenic translocations. In 
contrast, a small proportion of DLBCLs in HIV- infected cases and nearly all DLBCLs in 
HIV-uninfected cases were EBV–, with near even distribution of ABC and GCB 
phenotypes, and increased frequency of the MYC/IgHand IgH/BCL2translocations in GCB-
DLBCL. Future research evaluating the distribution and prognostic significance of 
molecular characteristics of DLBCLs in HIV-infected individuals should include patients 
treated with HAART and be able to measure the relationship of molecular characteristics to 
the degree of immunosuppression. In addition, analyses that directly compare a wider range 
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of genetic alterations in DLBCLs by HIV status would provide further insight into the 
pathogenetic mechanisms of lymphomagenesis.
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Overall survival following DLBCL diagnosis, by HIV status and cell of origin*. ABC, 
activated B-cell; DLBCL, diffuse large B-cell; GCB, germinal center B-cell. *Cell of origin 
was categorized using the Tally algorithm [25].
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Table I
Selected characteristics of 51 HIV-infected and 116 HIV-uninfected individuals with DLBCL.
Characteristic
HIV-infected HIV-uninfected
n (%) n (%)
Sex
 Male 51 (100) 56 (48)
 Female 0 (0) 60 (52)
Race/ethnicity
 White, non-Hispanic 25 (49) 59 (51)
 Hispanic 17 (33) 25 (22)
 Asian 2 (4) 14 (12)
 Black 4 (8) 9 (8)
 Other/unknown 3 (6) 9 (8)
Socioeconomic status*
 Highest 5 (10) 20 (17)
 Higher middle 9 (18) 16 (14)
 Middle 10 (20) 21 (18)
 Lower middle 11 (22) 27 (23)
 Lowest 12 (24) 23 (20)
 Unknown/missing 4 (8) 9 (8)
Age at DLBCL diagnosis (years)
 <40 31 (61) 11 (9)
 40&–59 20 (39) 31 (27)
 60–69 0 (0) 26 (22)
 70–79 0 (0) 30 (26)
 80+ 0 (0) 18 (16)
Year of DLBCL diagnosis
 <1990 11 (22) 47 (41)
 1991–1995 36 (71) 44 (38)
 >1996 4 (8) 25 (22)
Primary site of DLBCL
 Nodal 20 (39) 71 (61)
 Extranodal
   Brain/central nervous system 10 (20) 3 (3)
   Lower gastrointestinal tract† 7 (14) 7 (6)
   Stomach 4 (8) 10 (9)
   Other‡ 10 (20) 25 (22)
Vital status (as of 2011)
 Deceased 51 (100) 99 (85)
 Alive 0 (0) 17 (15)
HIV, human immunodeficiency virus; DLBCL, diffuse large B-cell lymphoma.
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*
Derived from education and income levels in each patient's census tract.
†
Lower gastrointestinal tract includes small or large intestine, anus and rectum.
‡
Other extranodal sites include lip, mouth, tonsil, nasal cavity, accessory sinuses, pleura, bone (n= 3), spleen, peritoneum (n= 2), connective tissue 
(n= 3), vagina, testis (n = 3), orbit and thyroid (n= 5) among HIV-uninfected cases, and tongue, parotid gland, tonsil, nasopharynx, liver (n= 2), 
accessory sinuses, lung (n= 2) and skin among HIV-infected cases.
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